Evelo Stock Analysis

EVLO -  USA Stock  

USD 4.88  0.33  6.33%

The big decline in price over the last few months for Evelo Biosciences could raise concerns from institutional investors as the firm it trading at a share price of 4.88 on 308,753 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Evelo Biosciences or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.79. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Evelo Biosciences partners.
Continue to Investing Opportunities.

Evelo Stock Analysis 

 
Refresh
The Evelo Biosciences stock analysis report makes it easy to digest most publicly released information about Evelo Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Evelo Stock analysis module also helps to analyze the Evelo Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Evelo Stock Analysis Notes

About 92.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.39. Evelo Biosciences had not issued any dividends in recent years. Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 90 people. To learn more about Evelo Biosciences call Simba Gill at 617 577 0300 or check out https://www.evelobio.com.

Evelo Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Evelo Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Evelo Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Evelo Biosciences generated a negative expected return over the last 90 days
Evelo Biosciences has high historical volatility and very poor performance
Evelo Biosciences has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (122.57 M).
Evelo Biosciences currently holds about 95.94 M in cash with (87.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.79.
Evelo Biosciences has a frail financial position based on the latest SEC disclosures
Over 92.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Plinio Mark D of 60000 shares of Evelo Biosciences subject to Rule 16b-3

Evelo Biosciences Upcoming and Recent Events

Earnings reports are used by Evelo Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evelo Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Evelo Largest EPS Surprises

Earnings surprises can significantly impact Evelo Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-10-29
2020-09-30-0.5-0.450.0510 
2019-08-06
2019-06-30-0.5821-0.65-0.067911 
2020-07-30
2020-06-30-0.715-0.630.08511 
View All Earnings Estimates

Evelo Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Evelo Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Evelo Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Evelo Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
4th of January 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
28th of December 2021
Unclassified Corporate Event
View
22nd of December 2021
Other Events
View
28th of October 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of September 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
27th of September 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
7th of September 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
29th of July 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Evelo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Evelo Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evelo Biosciences backward and forwards among themselves. Evelo Biosciences' institutional investor refers to the entity that pools money to purchase Evelo Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Belvedere Trading LlcCommon Shares241.1 K1.2 M
Ae Wealth Management LlcCommon Shares19.5 K119 K
Cutler Group LpCommon Shares6.1 K36 K
Cutler Group LpPut Options7.7 K31 K
National Bank Of CanadaCommon Shares100.01000
Signaturefd LlcCommon Shares78.00.0
Flagship Pioneering IncCommon Shares23 M162.1 M
Fmr LlcCommon SharesM56.4 M
Note, although Evelo Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evelo Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 277.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evelo Biosciences's market, we take the total number of its shares issued and multiply it by Evelo Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Evelo Profitablity

Evelo Biosciences' profitability indicators refer to fundamental financial ratios that showcase Evelo Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Evelo Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Evelo Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Evelo Biosciences' profitability requires more research than a typical breakdown of Evelo Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(1.10) (1.18) 
Return on Average Equity(1.78) (1.83) 
Return on Invested Capital(1.79) (1.93) 

Management Efficiency

The entity has return on total asset (ROA) of (65.54) % which means that it has lost $65.54 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (293.57) %, meaning that it created substantial loss on money invested by shareholders. Evelo Biosciences management efficiency ratios could be used to measure how well evelo biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.18. The value of Return on Average Equity is estimated to slide to -1.83. Evelo Biosciences Current Assets are quite stable at the moment as compared to the past year. The company's current value of Current Assets is estimated at 84.43 Million. Assets Non Current is expected to rise to about 24.4 M this year, although the value of Total Assets will most likely fall to about 101.6 M.
Last ReportedProjected for 2022
Book Value per Share 0.89  0.96 
Enterprise Value over EBIT(5.40) (5.83) 
Enterprise Value over EBITDA(6.85) (7.39) 
Price to Book Value 21.07  22.73 
Tangible Assets Book Value per Share 2.07  2.12 
Enterprise Value596.7 M491.5 M
Tangible Asset Value104.2 M101.6 M

Technical Drivers

As of the 26th of January, Evelo Biosciences shows the mean deviation of 3.61, and Coefficient Of Variation of (788.77). Evelo Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Evelo Biosciences, which can be compared to its rivals. Please confirm Evelo Biosciences variance, as well as the relationship between the value at risk and skewness to decide if Evelo Biosciences is priced favorably, providing market reflects its regular price of 4.88 per share. Given that Evelo Biosciences has jensen alpha of (0.50), we urge you to verify Evelo Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Evelo Biosciences Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Evelo Biosciences's momentum and the point in time when Evelo Biosciences has higher than normal probability directional change. View also all equity analysis or get more info about parabolic sar overlap studies indicator.

Evelo Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evelo Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evelo Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evelo Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Plinio Mark D few days ago via Macroaxis 
Acquisition by Plinio Mark D of 60000 shares of Evelo Biosciences subject to Rule 16b-3
David Epstein over three weeks ago via Macroaxis 
Exercise or conversion by David Epstein of 2874 shares of Evelo Biosciences subject to Rule 16b-3
David Epstein over a month ago via Macroaxis 
Exercise or conversion by David Epstein of 2873 shares of Evelo Biosciences subject to Rule 16b-3
David Epstein over two months ago via Macroaxis 
Exercise or conversion by David Epstein of 2873 shares of Evelo Biosciences subject to Rule 16b-3
David Epstein over three months ago via Macroaxis 
Exercise or conversion by David Epstein of 2874 shares of Evelo Biosciences subject to Rule 16b-3
Carriere Stephen J over three months ago via Macroaxis 
Evelo Biosciences exotic insider transaction detected
Mcinnes Iain B over three months ago via Macroaxis 
Acquisition by Mcinnes Iain B of 35000 shares of Evelo Biosciences subject to Rule 16b-3
David Epstein over six months ago via Macroaxis 
Acquisition by David Epstein of 34480 shares of Evelo Biosciences subject to Rule 16b-3
Andres Juan over six months ago via Macroaxis 
Acquisition by Andres Juan of 1810 shares of Evelo Biosciences subject to Rule 16b-3
Scavo Luca over six months ago via Macroaxis 
Acquisition by Scavo Luca of 4545 shares of Evelo Biosciences subject to Rule 16b-3
Mchugh Julie over six months ago via Macroaxis 
Acquisition by Mchugh Julie of 31380 shares of Evelo Biosciences subject to Rule 16b-3
Flagship Ventures Fund Iv General Partner Llc over six months ago via Macroaxis 
Evelo Biosciences exotic insider transaction detected

Evelo Biosciences Predictive Daily Indicators

Evelo Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evelo Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evelo Biosciences Forecast Models

Evelo Biosciences time-series forecasting models is one of many Evelo Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evelo Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Evelo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evelo Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evelo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Evelo Biosciences. By using and applying Evelo Stock analysis, traders can create a robust methodology for identifying Evelo entry and exit points for their positions.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 90 people.

Current Evelo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evelo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evelo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
20.9Buy5Odds
Evelo Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Evelo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Evelo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evelo Biosciences, talking to its executives and customers, or listening to Evelo conference calls.
Evelo Analyst Advice Details

Evelo Stock Analysis Indicators

Evelo Biosciences stock analysis indicators help investors evaluate how Evelo Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evelo Biosciences shares will generate the highest return on investment. By understating and applying Evelo Biosciences stock analysis, traders can identify Evelo Biosciences position entry and exit signals to maximize returns.
Quick Ratio4.63
Fifty Two Week Low4.65
Shares Short Prior Month5.45M
Average Daily Volume Last 10 Day244.01k
Average Daily Volume In Three Month245.67k
Shares Percent Shares Out10.29%
Short Percent Of Float23.54%
Forward Price Earnings-2.30
Float Shares27.08M
Fifty Two Week High19.93
Enterprise Value To Ebitda-2.66
Fifty Day Average7.63
Two Hundred Day Average9.99
Continue to Investing Opportunities. Note that the Evelo Biosciences information on this page should be used as a complementary analysis to other Evelo Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Evelo Stock analysis

When running Evelo Biosciences price analysis, check to measure Evelo Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evelo Biosciences is operating at the current time. Most of Evelo Biosciences' value examination focuses on studying past and present price action to predict the probability of Evelo Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Evelo Biosciences' price. Additionally, you may evaluate how the addition of Evelo Biosciences to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Evelo Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evelo Biosciences. If investors know Evelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Evelo Biosciences is measured differently than its book value, which is the value of Evelo that is recorded on the company's balance sheet. Investors also form their own opinion of Evelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Evelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evelo Biosciences' market value can be influenced by many factors that don't directly affect Evelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Evelo Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.